Octapharma AG, headquartered in Switzerland (CH), is a leading player in the pharmaceutical preparation manufacturing industry. Founded in 1983, the company has established a strong presence in Europe, North America, and Asia, focusing on the development and production of human proteins derived from human plasma and recombinant technologies.
Specialising in therapeutic areas such as immunology, haematology, and critical care, Octapharma is renowned for its high-quality products, including immunoglobulins, coagulation factors, and albumin. The company’s commitment to innovation and patient care has positioned it as a trusted provider in the global market, with notable achievements in expanding its product portfolio and enhancing patient outcomes. With a dedication to excellence, Octapharma continues to set benchmarks in the pharmaceutical industry.
+12 vs industry average
Octapharma’s score of 50 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Octapharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Octapharma's reported carbon emissions
Octapharma, a Pharmaceutical Preparation Manufacturing company headquartered in Switzerland (CH), is committed to climate action with a net-zero emissions goal by 2050. The company has achieved a 22% reduction in its overall emissions since 2019 and aims for a further 30% reduction by 2028. In its most recent reporting year, 2024, Octapharma reported Scope 1 emissions of approximately 24,948,000 kg CO2e. Scope 2 emissions, measured using the market-based approach, were approximately 28,987,000 kg CO2e, while the location-based measure was approximately 44,239,000 kg CO2e. Scope 3 emissions were significant, with purchased goods and services accounting for approximately 102,308,000 kg CO2e, followed by capital goods at approximately 93,515,000 kg CO2e, and employee commute at approximately 23,286,000 kg CO2e. Other reported Scope 3 categories include business travel (approximately 18,741,000 kg CO2e), waste generated in operations (approximately 21,093,000 kg CO2e), fuel and energy-related activities (approximately 15,450,000 kg CO2e), and upstream transportation and distribution (approximately 45,771,000 kg CO2e). For the 2023 reporting year, Octapharma's Scope 1 emissions were approximately 27,129,000 kg CO2e. Scope 2 emissions, market-based, were approximately 30,830,000 kg CO2e, and location-based were approximately 44,442,000 kg CO2e. Key Scope 3 categories for 2023 included purchased goods and services at approximately 93,126,000 kg CO2e, capital goods at approximately 72,037,000 kg CO2e, and employee commute at approximately 25,646,000 kg CO2e. Additional Scope 3 figures for 2023 encompass upstream transportation and distribution (approximately 45,551,000 kg CO2e), waste generated in operations (approximately 20,567,000 kg CO2e), fuel and energy-related activities (approximately 16,078,000 kg CO2e), and business travel (approximately 20,279,000 kg CO2e). Octapharma's total emissions for 2024 are approximately 262,454,000 kg CO2e (calculated from provided Scope 1, Scope 2 market-based, and Scope 3 categories). For 2023, total emissions are approximately 273,557,000 kg CO2e (calculated from provided Scope 1, Scope 2 market-based, and Scope 3 categories). The company's sustainability efforts are further detailed in its sustainability statements.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Octapharma’s Climate Goals (2030 & 2050)
2 goals2028
22% reduction in all scopes
Since 2019, we have reduced our overall emissions by 22% and aim to achieve a 30% reduction by 2028.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
7 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Octapharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project